Investigating the relationship between serum ACE 2 level and COVID-19 patients’ prognosis: a cross-sectional study - Mohammadi, Parsa; Varpaei, Hesam Aldin; Seifi, Arash; Miandoab, Sepideh Zahak; Beiranvand, Saba; Mobaraki, Sahar; Mohammadi, Mostafa (medRxiv, 2021)
Background The only known receptor for this virus in the human body is ACE2, the same known receptor for the SARS virus.Material and Method In this single-center cross-sectional study, 38 hospitalized adult (≥18 years) patients with laboratory-confirmed COVID-19 were identified in the infectious disease ward in Imam Khomeini hospital complex. The study also has been approved in ethics committee of Tehran University of medical sciences with ethic code: 99/11/101/16529. Data were analyzed using SPSS 25. p < 0.05 was considered statistically significant when a two-tailed test was performed.Result Among the 38 patients, the mean age was 64.13 years, 52.6% were male, 42% were PCR test positive and 39.5% was expired. The most common presenting symptoms were cough (80%), fever (75.5%), dyspnea (60.5%), myalgias (35.8%), diarrhea (20%), and nausea and vomiting (15%). There were not any significant differences between expired and discharged group in terms of serum ACE2 level. Results were similar between discharged and expired patients in the subgroup analysis of 38 patients.Conclusion It seems that serum ACE 2 level is not correlated with COVID-19 patients’ prognosis. However, it seems that more researches are required to confirm supposed association between serum ACE2 level and inflammatory biomarkers, clinical outcome, and patient’s survival.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received no funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study approved in ethics committee of Tehran University of medical sciences with ethic code: 99/11/101/16529.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTehran University medical sciences.